New drug combo tested for Tough-to-Treat blood cancer
NCT ID NCT01615029
Summary
This study tested the safety of adding a new drug called daratumumab to two existing medications (lenalidomide and dexamethasone) for people with multiple myeloma that had returned after previous treatments. The trial involved 45 participants and aimed to find the safest and most effective dose of this three-drug combination. Researchers measured how well the treatment worked by tracking cancer response rates and how long patients lived without their disease getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Boston, Massachusetts, United States
-
Study site
Copenhagen Ø, Denmark
-
Study site
Vejle, Denmark
-
Study site
Lille, France
-
Study site
Nantes, France
-
Study site
Vandœuvre-lès-Nancy, France
-
Study site
Utrecht, Netherlands
-
Study site
London, United Kingdom
Conditions
Explore the condition pages connected to this study.